Table 1. Baseline clinical and laboratory parameters in patients with or without subsequent HCC development during the surveillance period.
| Parameters | All patients (n = 6,453) | HCC group (n = 367) | No HCC group (n = 6,086) | P value* |
|---|---|---|---|---|
| Age (year) | 46 ± 12 | 54 ± 10 | 46 ± 12 | < 0.0001 |
| Gender, male (%) | 3,814 (59) | 261 (72) | 3,553 (58) | < 0.0001 |
| Liver cirrhosis (%) | 1,342 (21) | 294 (80) | 1,048 (17) | < 0.0001 |
| Nucleos(t)ide analog therapy (%) | 2981 (46) | 312 (85) | 2669 (44) | < 0.0001 |
| AST (IU/L) | 30 (7–4898) | 50 (13–449) | 29 (7–4898) | 0.0816 |
| ALT (IU/L) | 34 (3–6824) | 49 (12–1256) | 33 (3–6824) | 0.8682 |
| Albumin (mg/dL) | 4.2 ± 0.4 | 3.8 ± 0.5 | 4.3 ± 0.4 | < 0.0001 |
| Bilirubin (mg/dL) | 0.9 (0.2–24.2) | 1.1 (0.2–14.6) | 0.9 (0.2–24.2) | < 0.0001 |
| Prothrombin time (INR) | 1.08 ± 0.18 | 1.19 ± 0.18 | 1.07 ± 0.17 | < 0.0001 |
| Platelet count (x1000 /mm3) | 191 ± 66 | 126 ± 55 | 195 ± 64 | < 0.001 |
| HBV DNA (IU/mL) | 5,124 (25–30,400,000) | 385,864 (25–30,300,000) | 3864 (25–30,400,000) | 0.0183 |
| AFP (ng/mL) | 3.0 (0.1–4000) | 8.0 (0.3–4000) | 3.0 (0.1–3573) | < 0.001 |
| AFP > 10 ng/mL | 782 (12) | 148 (40) | 634 (10) | < 0.001 |
*HCC vs. no HCC group
Continuous values are expressed as mean ± standard deviation (SD) or median (range), and categorical values are expressed as number (%).